1stOncology™: Cancer Intelligence Service – Page 3697 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023

On August 28, 2023 HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, reported that Fierce Biotech has named it as one of 2023’s "Fierce 15" biotechnology companies (Press release, HiFiBiO Therapeutics, AUG 28, 2023, View Source [SID1234634713]). The annual special report features the most innovative and promising early-stage biotechnology companies in the industry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"HiFiBiO Therapeutics is at the forefront of harnessing single-cell insights to bring innovative immunomodulatory therapeutics into the clinic," remarked Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO Therapeutics. "The Fierce 15 recognition reflects our passionate dedication to patients with unmet medical needs, and further highlights our unique Drug Intelligence Science (DIS) approach to enhance the probability of success of immunotherapy from targets to drugs to patients."

HiFiBiO Therapeutics is differentiated by its pioneering DIS approach which combines a proprietary microfluidic single-cell platform with advanced AI/ML-based data analytics to gain unprecedented insights into human disease biology. Through this high-resolution translational approach, HiFiBiO Therapeutics has advanced three programs into Phase 1 trials, a first-in-class TNFR2 agonist (HFB200301, NCT05238883), a best-in-class BTLA antagonist (HFB200603, NCT05789069), and a 2nd generation OX40 agonist (HFB301001, NCT05229601).

Since 2017, HiFiBiO Therapeutics has built a sustainable pipeline targeting key mechanisms of immune modulation, with eight clinical candidates discovered, mainly across oncology and autoimmune diseases. With more than $180M in financing from world-class investors and an experienced top-tier scientific and clinical team, HiFiBiO is well-positioned to deliver effective therapeutic solutions for patients globally.

"For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the ‘Fierce 15’ special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market," said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare. "Our special report celebrates innovation and creativity in the face of intense competition."

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

On August 28, 2023 Genmab A/S (Nasdaq: GMAB) reported that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 3:35 PM EDT / 9:35 PM CEST on September 12, 2023 (Press release, Genmab, AUG 28, 2023, View Source [SID1234634712]). A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at View Source

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On August 28, 2023 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported the grant of inducement awards to three employees between August 14, 2023 and August 28, 2023 in connection with the employees’ commencement of employment at CymaBay (Press release, CymaBay Therapeutics, AUG 28, 2023, View Source [SID1234634711]). The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 270,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.

These stock option grants had exercise prices of $12.07, $12.40 and $13.81 per share, respectively, which were equal to the closing price of CymaBay’s common stock on the applicable grant dates for the stock options. The stock options will vest and become exercisable as to 25% of the underlying shares on the first anniversary of their respective grant date, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments from the first anniversary of their respective grant date, subject to the applicable employee’s continued employment with CymaBay on such vesting dates.

BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES

On August 28, 2023 Bio-Techne Corporation (NASDAQ: TECH) reported that it will present at the following investor healthcare conferences (Press release, Bio-Techne, AUG 28, 2023, View Source [SID1234634710]):

2023 Wells Fargo Healthcare Conference
September 6, 2023
10:15 AM EDT

Baird 2023 Global Healthcare Conference
September 12, 2023
4:55 PM EDT

Morgan Stanley 21st Annual Global Healthcare Conference
September 13, 2023
2:55 PM EDT

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Novocure to Participate in Upcoming Investor Conferences

On August 25, 2023 Novocure (NASDAQ: NVCR) reported that management will participate in two upcoming investor conferences (Press release, NovoCure, AUG 25, 2023, View Source [SID1234634704]). William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 2023 Wells Fargo Healthcare Conference on September 7, 2023. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 12:45 p.m. ET, as well as one-on-one meetings with investors throughout the event.

Mr. Doyle and Ms. Cordova will also participate in the Morgan Stanley Global Healthcare Conference on September 13, 2023. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 8:10 a.m. ET, and one-on-one meetings with investors throughout the event.

Live audio webcasts of these presentations can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.